Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $423 | $270 | $220 | $39 |
| % Growth | 56.6% | 22.7% | 471.2% | – |
| Cost of Goods Sold | $61 | $57 | $23 | $9 |
| Gross Profit | $362 | $214 | $197 | $29 |
| % Margin | 85.6% | 79.1% | 89.6% | 76.4% |
| R&D Expenses | $112 | $76 | $65 | $99 |
| G&A Expenses | $157 | $0 | $0 | $0 |
| SG&A Expenses | $168 | $129 | $98 | $86 |
| Sales & Mktg Exp. | $11 | $0 | $0 | $0 |
| Other Operating Expenses | $128 | $33 | $24 | $1 |
| Operating Expenses | $408 | $239 | $188 | $186 |
| Operating Income | -$46 | -$25 | $10 | -$157 |
| % Margin | -10.8% | -9.3% | 4.4% | -406.4% |
| Other Income/Exp. Net | $9 | $9 | $1 | $0 |
| Pre-Tax Income | -$36 | -$17 | $11 | -$157 |
| Tax Expense | $7 | -$31 | -$172 | $1 |
| Net Income | -$43 | $14 | $183 | -$158 |
| % Margin | -10.2% | 5.2% | 83.3% | -409.7% |
| EPS | -0.6 | 0.2 | 2.64 | -2.3 |
| % Growth | -400% | -92.4% | 214.8% | – |
| EPS Diluted | -0.6 | 0.2 | 2.6 | -2.3 |
| Weighted Avg Shares Out | 71 | 70 | 69 | 69 |
| Weighted Avg Shares Out Dil | 71 | 72 | 70 | 69 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $9 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$44 | -$23 | $12 | -$154 |
| % Margin | -10.4% | -8.5% | 5.5% | -400.3% |